Monoprost Duo (Latanoprost, Timolol)

Latanoprost/Timolol, the active ingredient in Monoprost Duo, is a prostaglandin analog / beta‑blocker presented as eye drops for ocular use. It lowers intra‑ocular pressure by increasing aqueous outflow and reducing aqueous production, thereby managing open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monoprost Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to regulated ophthalmic medicines. The product complies with EU pharmacopeial standards and is distributed under strict quality‑assurance protocols.

Monoprost Duo, a combination prostaglandin analog and beta‑blocker, is used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Post‑surgical ocular pressure spikes: helps control pressure after ocular surgery.

Monoprost Duo may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (eye redness). - Increased eyelash length or pigmentation changes.

Serious or Rare Side Effects: - Severe allergic reaction with swelling of the eyelids. - Persistent ocular pain or inflammation. - Sudden loss of vision. - Systemic bradycardia or hypotension. - Exacerbation of asthma or COPD symptoms.

Before prescribing Monoprost Duo, clinicians should consider several safety aspects.

Assess baseline intra‑ocular pressure and visual field status. Monitor for beta‑blocker contraindications such as asthma, COPD, or bradycardia. Avoid use in patients with known hypersensitivity to any component. Exercise caution in pregnancy or breastfeeding; risk data are limited. Do not combine with other prostaglandin analog eye drops. Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Monoprost Duo can interact with other medications affecting ocular pressure or systemic beta‑adrenergic activity.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol) – additive bradycardia. - Sympathomimetic ophthalmic agents (e.g., phenylephrine) – reduced IOP‑lowering effect. - Concurrent prostaglandin analog eye drops – risk of excessive ocular effects.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitor eye drops (e.g., dorzolamide) – additive IOP reduction. - Systemic antihypertensive drugs – monitor blood pressure. - Anticholinergic ophthalmic preparations – may affect ocular surface tolerance.